HTG MOLECULAR DIAGNOSTICS, INC. Financials HTG Molecular Diagnostics, Inc.
Equities
HTGMQ
US40434H3021
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0025 USD | +66.67% |
|
0.00% | +92.31% |
| 2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
| 2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 25.39 | 72.38 | 40.74 | 22.7 | 41.02 | 3.674 |
| Enterprise Value (EV) 1 | 32.19 | 57.94 | 24.73 | 11.71 | 35.28 | 0.2623 |
| P/E ratio | -1.13 x | -4.25 x | -1.39 x | -1.19 x | -2.19 x | -0.16 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.72 x | 3.37 x | 2.12 x | 2.66 x | 4.61 x | 0.58 x |
| EV / Revenue | 2.18 x | 2.69 x | 1.29 x | 1.37 x | 3.96 x | 0.04 x |
| EV / EBITDA | -1.95 x | -3.94 x | -1.4 x | -0.64 x | -1.89 x | -0.01 x |
| EV / FCF | -3.14 x | -7.05 x | -1.82 x | -1.71 x | -3.18 x | -0.03 x |
| FCF Yield | -31.9% | -14.2% | -54.8% | -58.3% | -31.5% | -3,903% |
| Price to Book | -9.24 x | 3.44 x | 1.7 x | 1.72 x | 3.95 x | 1.64 x |
| Nbr of stocks (in thousands) | 69.5 | 158 | 322 | 395 | 631 | 921 |
| Reference price 2 | 365.4 | 457.2 | 126.3 | 57.48 | 65.04 | 3.990 |
| Announcement Date | 3/23/18 | 3/7/19 | 3/25/20 | 3/25/21 | 3/29/22 | 3/30/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 14.76 | 21.5 | 19.2 | 8.549 | 8.907 | 6.366 |
| EBITDA 1 | -16.48 | -14.69 | -17.7 | -18.24 | -18.63 | -20.24 |
| EBIT 1 | -17.72 | -16.16 | -18.96 | -19.59 | -19.35 | -20.83 |
| Operating Margin | -120.08% | -75.15% | -98.73% | -229.1% | -217.27% | -327.19% |
| Earnings before Tax (EBT) 1 | -18.96 | -16.45 | -19.29 | -20.86 | -17.12 | -21.58 |
| Net income 1 | -18.96 | -16.45 | -19.3 | -20.87 | -17.15 | -21.59 |
| Net margin | -128.46% | -76.52% | -100.49% | -244.13% | -192.49% | -339.2% |
| EPS 2 | -322.0 | -107.6 | -91.17 | -48.16 | -29.66 | -24.28 |
| Free Cash Flow 1 | -10.27 | -8.22 | -13.56 | -6.834 | -11.1 | -10.24 |
| FCF margin | -69.57% | -38.22% | -70.59% | -79.94% | -124.66% | -160.79% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/23/18 | 3/7/19 | 3/25/20 | 3/25/21 | 3/29/22 | 3/30/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.583 | 1.435 | 2.074 | 2.52 | 2.877 | 1.184 | 1.492 | 1.251 | 2.439 | 1.033 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.023 | -4.582 | -4.082 | -4.23 | -4.93 | -6.254 | -5.677 | -4.348 | -4.551 | -5.013 |
| Operating Margin | -155.75% | -319.25% | -196.8% | -167.85% | -171.34% | -528.01% | -380.6% | -347.6% | -186.55% | -485.48% |
| Earnings before Tax (EBT) 1 | -4.288 | -4.846 | -2.599 | -4.489 | -5.189 | -6.497 | -5.883 | -4.515 | -4.689 | -5.053 |
| Net income 1 | -4.29 | -4.848 | -2.615 | -4.491 | -5.191 | -6.498 | -5.888 | -4.516 | -4.693 | -5.055 |
| Net margin | -166.09% | -337.83% | -126.07% | -178.17% | -180.44% | -548.57% | -394.76% | -361.04% | -192.37% | -489.56% |
| EPS 2 | -10.92 | -9.600 | -4.680 | -7.200 | -8.280 | -9.720 | -6.480 | -4.920 | -3.160 | -2.280 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/25/21 | 5/13/21 | 8/12/21 | 11/10/21 | 3/29/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/30/23 | 5/10/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 6.8 | - | - | - | - | - |
| Net Cash position 1 | - | 14.4 | 16 | 11 | 5.74 | 3.41 |
| Leverage (Debt/EBITDA) | -0.4128 x | - | - | - | - | - |
| Free Cash Flow 1 | -10.3 | -8.22 | -13.6 | -6.83 | -11.1 | -10.2 |
| ROE (net income / shareholders' equity) | 438% | -182% | -85.6% | -109% | -138% | -273% |
| ROA (Net income/ Total Assets) | -55.8% | -31.1% | -26.7% | -30.5% | -36.8% | -54% |
| Assets 1 | 33.99 | 52.97 | 72.38 | 68.47 | 46.54 | 40.01 |
| Book Value Per Share 2 | -39.50 | 133.0 | 74.30 | 33.40 | 16.40 | 2.440 |
| Cash Flow per Share 2 | 129.0 | 53.10 | 23.60 | 51.70 | 15.20 | 5.520 |
| Capex 1 | 1.02 | 0.95 | 1.1 | 0.45 | 0.64 | 0.02 |
| Capex / Sales | 6.91% | 4.42% | 5.74% | 5.31% | 7.23% | 0.36% |
| Announcement Date | 3/23/18 | 3/7/19 | 3/25/20 | 3/25/21 | 3/29/22 | 3/30/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +92.31% | 5.54K | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- HTGMQ Stock
- Financials HTG Molecular Diagnostics, Inc.
